Commentary on Murray and Hernán

Clinical Trials

Volumn 13, Issue 4, 2016, Pages 379-381

  Wittes, Janet ^a  

^a University of Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CLINICAL STUDY; CORONARY DRUG PROJECT; DEATH; FALLING; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL ANALYSIS; NOTE; PATIENT COMPLIANCE; PERCEPTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; SENSITIVITY ANALYSIS; TRAINING; TREATMENT REFUSAL;

EID: 84979085558     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774516634336     Document Type: Note

References (4)

1. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-98.
2. Robins JM., The control of confounding by intermediate variables. Stat Med 1989; 8: 679-701.
3. Murray E, Hernán M,. Adherence adjustment in the Coronary Drug Project: a call for better per-protocol effect estimates in randomized trials. Clin Trials 2016; 13: 372-378.
4. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038-1041.